LMTK3 and breast carcinoma: However, we did not find any germline variations in LMTK3 associated with breast cancer recurrence in our MA.27 cohort, suggesting a LMTK3 upstream regulator such as MIR2052HG might be the driving factor influencing this clinical phenotype.